Transforming Cancer Therapy: Next-Generation Bispecific Nanobody Targeting CD3 Complex and NECTIN4

VHH-P572 is a humanized nanobody designed to target both the CD3 Complex (T Cell Receptor Complex) and nectin cell adhesion molecule 4 (NECTIN4). Currently under development in the Biological Testing phase, VHH-P572 exhibits promise for cancer treatment by harnessing advanced antibody engineering. By engaging both the immune system and tumor cells, this innovative bispecific construct aims to provide a new therapeutic avenue in oncology. The dual-targeting of CD3 Complex (T Cell Receptor Complex) and nectin cell adhesion molecule 4 (NECTIN4) underscores VHH-P572’s potential to address key challenges in solid and hematologic malignancies. This program exemplifies the next generation of cancer immunotherapies underpinned by robust molecular design.

Licensing Opportunity

VHH-P572 is available for out-licensing and strategic partnership. We welcome collaborations with industry leaders and academic institutions interested in advancing next-generation cancer immunotherapies.

Development Phase

Modality

VHH-P572 is built as a tetravalent, symmetric bispecific antibody fusion. It incorporates four anti-NECTIN4 single-domain antibodies—nanobodies—each efficiently fused via flexible GS linkers to the N-terminus of the variable regions of a complete anti-CD3 antibody backbone, which is engineered for improved effector function via specific Fc mutations. The small size and single-domain format of the nanobodies confer superior tissue penetration and enhanced stability relative to conventional antibodies, which is especially advantageous for targeting cancer cells within dense tumor microenvironments. This modular design not only facilitates precise dual targeting of tumor antigens and T-cells, but also supports manufacturability and versatility in drug development.

Target

The CD3 Complex is a multi-subunit protein expressed predominantly on the surface of T cells, playing a crucial role in T cell activation and signal transduction. NECTIN4 is a cell adhesion molecule primarily located on epithelial cells and is frequently overexpressed in various cancer types, including solid tumors. Both CD3 Complex and NECTIN4 serve as strategic therapeutic targets due to their roles in immune modulation and tumor biology. While CD3 Complex engagement efficiently recruits and activates T cells, targeting NECTIN4 allows for selective discrimination of malignant cells. VHH-P572’s simultaneous targeting of CD3 Complex and NECTIN4 maximizes tumor specificity and immune redirection, addressing the therapeutic challenge of precise cancer cell elimination while minimizing off-tumor toxicities. The dual focus on CD3 Complex and NECTIN4 improves the asset’s attractiveness as a next-generation immuno-oncology candidate.

Mechanism of Action

VHH-P572 operates by simultaneously binding to CD3 Complex on T cells and NECTIN4 on cancer cells. As a T cell engager, this bispecific nanobody fusion brings the patient’s own T cells into close proximity with NECTIN4-expressing tumor cells, initiating targeted cytotoxic activity through immune synapse formation and direct cell killing. By modulating these key signal transduction pathways, VHH-P572 enhances immune effector functions against cancer cells while leveraging the precision of nanobody technology. The modular bispecific scaffold not only provides flexibility for future platform extensions—such as antibody-drug conjugates or additional dual-specific formats—but also underscores broad utility for a variety of oncology indications with unmet needs.

Cancer

Cancer remains a leading cause of morbidity and mortality worldwide, marked by the uncontrolled growth and dissemination of abnormal cells. The spectrum of cancer includes a wide range of solid and hematologic malignancies, presenting significant clinical and societal challenges. Current mainstays of treatment encompass surgery, chemotherapy, radiotherapy, immunotherapy, and molecular targeted therapies. Despite advances, many patients experience disease progression or relapse due to intrinsic or acquired resistance, toxicity, or lack of tumor specificity in conventional therapies. There is thus a critical demand for innovative approaches that achieve precise tumor targeting while engaging the immune system. Bispecific nanobody therapeutics like VHH-P572, which redirect T cell activity towards NECTIN4-expressing cancer cells, offer the potential to overcome key shortcomings of existing therapies and expand effective treatment options for patients with diverse cancers.